5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES

5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES

Background: The selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor empagliflozin leads to improved cardiovascular, renal and heart failure outcome in secondary prevention. To better understand these effects, we examined vascular function and central hemodynamics. Methods: In this prospecti...

Full description

Bibliographic Details
Main Authors:	Christian Ott, Kristina Striepe, Agnes Jumar, Marina Karg, Markus Schneider, Dennis Kannenkeril, Roland Schmieder
Format:	Article
Language:	English
Published:	BMC 2017-12-01
Series:	Artery Research
Online Access:	https://www.atlantis-press.com/article/125930220/view

Similar Items

4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes
by: Christian Ott, et al.
Published: (2020-02-01)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
by: Agnes Bosch, et al.
Published: (2019-03-01)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
by: Christian Ott, et al.
Published: (2021-09-01)

Association of Noise Annoyance with Measured Renal Hemodynamic Changes
by: Dennis Kannenkeril, et al.
Published: (2021-04-01)

P142 EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETES
by: Christian Ott, et al.
Published: (2018-12-01)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
by: Agnes Bosch, et al.
Published: (2023-06-01)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
by: Dennis Kannenkeril, et al.
Published: (2018-09-01)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
by: Julie Kolwelter, et al.
Published: (2021-12-01)

Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
by: Mawadah Staef, et al.
Published: (2023-06-01)

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study
by: Julie Kolwelter, et al.
Published: (2022-07-01)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
by: M. V. Karg, et al.
Published: (2018-01-01)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
by: R. Pietschner, et al.
Published: (2021-11-01)

Is vascular remodelling in patients with chronic heart failure exaggerated?
by: Robert Pietschner, et al.
Published: (2023-02-01)

Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus.
by: Agnes Jumar, et al.
Published: (2016-01-01)

4.1 EFFECT OF ALISKIREN ON VASCULAR REMODELING IN SMALL RETINAL CIRCULATION
by: Christian Ott*, et al.
Published: (2015-11-01)

Retinal vascular resistance in arterial hypertension
by: Dennis Kannenkeril, et al.
Published: (2018-03-01)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
by: Alexey V. Karpushev, et al.
Published: (2022-08-01)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
by: Marvin Heimke, et al.
Published: (2022-10-01)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
by: Sebastian Steven, et al.
Published: (2017-10-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
by: Ellen Vercalsteren, et al.
Published: (2024-02-01)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
by: Raj Verma, et al.
Published: (2023-06-01)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
by: Chenguang Li, et al.
Published: (2019-02-01)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019-04-01)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
by: Hiroyuki Takahashi, et al.
Published: (2019-07-01)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023-04-01)

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes
by: Zsolt Szekeres, et al.
Published: (2023-02-01)

The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice
by: Jungmi Choi, et al.
Published: (2023-03-01)

SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
by: Damilola D. Adingupu, et al.
Published: (2019-02-01)

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.
by: Sam Tsz Wai Cheng, et al.
Published: (2016-01-01)

Renal effects and nephroprotection induced by SGLT2 inhibitor Empagliflozin in patients with Diabetes Mellitus: a literature review
by: Luis E. Morales-Buenrostro, et al.
Published: (2017-01-01)

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
by: Martin Benedikt, et al.
Published: (2023-07-01)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
by: Irina Claudia Anton, et al.
Published: (2022-06-01)

Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease
by: Pasquale Mone, et al.
Published: (2024-02-01)

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure a multinational randomized trial (The EMPULSE Trial)
by: Souvik Sardar
Published: (2022-01-01)

13.11 EFFECTS OF DAPAGLIFLOZIN ON EARLY ALTERATIONS OF THE MICRO- AND MACROCIRCULATION
by: Christian Ott, et al.
Published: (2016-11-01)

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms
by: Lan Cheng, et al.
Published: (2022-03-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats
by: Alana Aragón-Herrera, et al.
Published: (2023-05-01)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
by: Alana Aragón-Herrera, et al.
Published: (2022-02-01)